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Abstract
Psychological and pharmacological interventions for binge-eating disorder have previously demonstrated efficacy (compared with 
placebo or waitlist control); thus, we aimed to expand that literature with a review of comparative effectiveness. We searched 
MEDLINE,® EMBASE,® Cochrane Library, Academic OneFile, CINAHL® for binge-eating disorder treatment articles and selected 
studies using predetermined inclusion and exclusion criteria. Data were sufficient for network meta-analysis comparing two 
pharmacological interventions; psychological interventions were analysed qualitatively. In all, 28 treatment comparisons were included 
in this review: one pharmacological comparison (second-generation antidepressants versus lisdexamfetamine) and 26 psychological 
comparisons. Only three statistically significant differences emerged: lisdexamfetamine was better at increasing binge abstinence than 
second-generation antidepressants; therapist-led cognitive behavioural therapy was better at reducing binge-eating frequency than 
behavioural weight loss, but behavioural weight loss was better at reducing weight. The majority of other treatment comparisons revealed 
few significant differences between groups. Thus, patients and clinicians can choose from several effective treatment options.
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Introduction
Binge-eating disorder (BED)—characterized by consuming large
amounts of food with an associated sense of loss of control—
merits particular attention by clinicians and patients alike given
its elevation to an independent diagnosis in the most recent
version of the Diagnostic and Statistical Manual (DSM-5)
(American Psychiatric Association, 2013). BED is common
among adults in the United States; lifetime prevalence is estimated
at 2.8% (Hudson, Hiripi, Pope, & Kessler, 2007). Prevalence is
higher among obese individuals, particularly those seeking
treatment for weight loss (Bruce & Wilfley, 1996; Grucza,
Przybeck, & Cloninger, 2007; Spitzer et al., 1993a; Spitzer et al.,
1993b). BED is considered to be a public health problem because
of its impact on psychiatric, physical, and social functioning
(Hudson et al., 2007; Kessler et al., 2013; Whisman, Dementyeva,
Baucom, & Bulik, 2012).
BED thus warrants a rigorous systematic review; this paper
presents the comparative effectiveness results of treatments
for individuals with this condition. It reports on and updates
findings from a larger systematic review on the management
and outcomes of BED recently completed for the US Agency
for Healthcare Research and Quality by the RTI-University of
North Carolina Evidence-based Practice Center (Berkman
et al., 2015); that systematic review had updated our 2006
review on BED and related eating disorders (Berkman et al.,
2006; Brownley, Berkman, Sedway, Lohr, & Bulik, 2007).
Findings from efficacy studies about the benefits and harms
of psychological and pharmacologic therapies for adults with
BED were published in June 2016 (Brownley et al., 2016).
Cognitive behavioural therapy (CBT), second-generation
antidepressants (SGAs), lisdexamfetamine, and topiramate all
reduced binge eating and related psychopathology; the latter
two medications also produced reductions in weight. Thus,
each of these interventions offered benefits. Some side effects
were associated with pharmaceutical interventions (such as
those from lisdexamfetamine for gastrointestinal upset or
headaches, from topiramate for sympathetic nervous system
treatments are most beneficial for individuals with BED. Being
able to draw defensible conclusions has become more critical with
BED now an independent disorder in the DSM-5, the increasing
awareness about the condition, and the predicted increase in
treatment seeking (Marek, Ben-Porath, Ashton, & Heinberg,
2014; Trace et al., 2012).
We present here the specific results from our larger systematic
review about the comparative effectiveness of selected treatments
for adults with BED. Of particular importance are four major sets
of outcomes: binge-eating outcomes (e.g., abstinence and binge-
eating frequency), eating-related psychopathology outcomes
(e.g., obsessions and compulsions), weight-related outcomes [e.
g., body mass index (BMI)], and general psychological outcomes
(e.g., depressive symptoms). Other outcomes, such as quality-of-
life benefits and risks of adverse events, are of interest as well.
We also discuss the clinical and scientific implications of our




Eligible studies for these specific analyses were randomized
controlled trials (RCTs) with sample sizes of 10 or more and
published in English. Detailed information on inclusion and
exclusion criteria is available in the full report (Berkman et al.,
2015). Using the population, intervention, comparators,
outcomes, timing, and settings (PICOTS) framework, our
principal inclusion criteria pertaining to this paper included the
following:
• Individuals of all races, ethnicities, and cultural groups who
meet DSM-IV or DSM-5 criteria for BED;
• Psychological, behavioural, pharmacological, or
complementary and alternative treatments or combinations of
treatments;
• Two or more active comparators (from PICOTS criteria);
• Final health outcomes or intermediate health outcomes, such as
biomarkers, that can be linked directly to final physical health
outcomes;
• Outcomes evaluated at the end of treatment or later followup
(or both); and
• No limits on settings.
Data sources and search strategy
An experienced research librarian searched MEDLINE,®
EMBASE,® Cochrane Library, Academic OneFile, and the
Cumulative Index to Nursing and Allied Health Literature
(CINAHL®) using a predefined list of search terms and medical
subject headings for articles indexed through 17 November
2015. The same librarian updated the MEDLINE® search to find
any relevant articles indexed through 12 May 2016. Appendix A
presents the full search strategy. We searched for unpublished
and grey literature from trial registries (e.g., ClinicalTrials.gov).
For older studies on BED, we searched the relevant portion of
the reference list of our 2006 review, Management of Eating
Disorders; however, we did not rely on the earlier review to
arousal, and from SGAs for sleep disturbance); no adverse 
effects were reported for psychological treatments although 
they were not universally assessed (Brownley et al., 2016).
As a complement to efficacy studies, comparative effectiveness 
reviews are designed to help inform health care decisions by 
comparing outcomes, drawn ideally from head-to-head 
comparative trials, from among treatments that have already 
demonstrated efficacy (i.e., those with active comparators rather 
than placebo, waitlist, or usual care). Such reviews help inform 
researchers, patients, and clinicians alike on which of the available 
efficacious interventions might work best for the given population 
or illness. Comparative effectiveness reviews contribute to the 
evidence base necessary to make decisions about optimal 
treatments (i.e., increasing benefits and minimizing harms). A 
comparative effectiveness review for BED is thus both timely 
and appropriate given that the efficacy of several interventions 
has been established (Berkman et al., 2015; Brownley et al., 
2016), but that relatively little is understood regarding which 
interventions for BED may be more effective and for whom.
Several approaches for treating BED patients have been 
evaluated in the literature; these include both pharmacological 
and psychological interventions (Berkman et al., 2015; 
Brownley et al., 2016; Brownley et al., 2007; Peat, Brownley, 
Berkman, & Bulik, 2012). With regard to pharmacological 
interventions, studies have evaluated the efficacy of various 
antidepressants, appetite suppressants, and anticonvulsant 
medications. In 2015, lisdexamfetamine (a central nervous 
system stimulant originally marketed as a drug for attention 
deficit hyperactivity disorder) became the first medication that 
the US Food and Drug Administration (FDA) approved for 
treating BED patients (U.S. Food and Drug Administration, 
2015). For psychological interventions, the majority of studies 
have involved CBT, interpersonal psychotherapy (IPT), and 
behavioural weight loss (BWL).
Within these larger categories of psychological interventions, 
investigators have developed distinct variations for delivering the 
treatments (e.g., therapist-led and self-help; individual and group 
format; different treatment durations). Researchers developed the 
variations to try to answer important empirical questions that 
would deconstruct the essential components of treatment (e.g., 
scalability and level of necessary therapist involvement). This 
practice, however, has fragmented the available evidence on the 
psychological management of BED. The result is largely a body 
of literature of ‘one-off’ studies on psychological management 
that is difficult to evaluate collectively. Policymakers, however, 
require actionable evidence on differences across treatment 
modalities, particularly in light of an anticipated increased focus 
on BED in clinical care, corresponding to its recent DSM-5 
designation as a distinct eating disorder, and concern about the 
paucity of BED psychological treatment expertise available 
generally. Thus, efforts to synthesize the literature are crucial at 
this time.
Complicating this challenge are the lack of replication trials 
across both pharmacological and psychological interventions 
and a paucity of well-designed studies that directly compare the 
core psychological treatments and their variants (e.g., therapist-
led CBT versus self-help CBT). Together, these limitations hinder 
the field’s ability to draw meaningful conclusions about which
treatment effects in the absence of head-to-head data that are
frequently unavailable. Thus, researchers can pool results from
separate trials involving the same population, comparison (e.g.,
placebo or wait-list), and outcomes to better visualize the broader
picture of evidence and help identify which treatments might be
more effective.
We conducted network meta-analyses using a graph-based
frequentist approach described by Rücker (2012) and imple-
mented in the NETMETA package in R (https://cran.r-project.
org/web/packages/netmeta/index.html) (Neupane, Richer,
Bonner, Kibret, & Beyene, 2014). In addition, as a sensitivity check,
we fit the models using a Bayesian approach (van Valkenhoef et al.,
2012) implemented in the GEMTC package in R (https://cran.r-
project.org/web/packages/gemtc/gemtc.pdf) (van Valkenhoef &
Kuiper, 2016); it produced similar results (not shown). Results
from network (also known as indirect) meta-analyses tend to agree
with head-to-head trials when component studies are similar and
treatment effects are expected to be consistent in patients in
different trials (Glenny et al., 2005). To conduct network meta-
analyses, we included all the placebo-controlled pharmaceutical
trials that were homogenous in study populations and outcome
assessments. To account for potential between-study hete-
rogeneity, we estimated the indirect treatment effects based on
random effects models. We estimated relative risks and 95%
confidence intervals (CIs) as the effect measures for categorical
outcomes and mean differences (and 95% CIs) for continuous
outcomes [binge-eating days and scores on the Yale Brown
Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-
BE)] (Deal, Wirth, Gasior, Herman, & McElroy, 2015).
Data synthesis of psychological interventions
Although our search did reveal head-to-head comparisons of
psychological interventions, the psychological interventions trials
did not provide sufficiently similar data to meet the minimum
threshold of three similar studies for pooled analysis. For that
reason, we analysed these data only qualitatively.
Qualitative data synthesis was a collaborative process among
senior reviewers based on an existing protocol; we based our
groupings of studies and subsequent findings on judgments about
the similarity of interventions and outcomes measured and the
homogeneity of patient populations. For example, in our
judgment therapeutic interventions involving individual-based
versus group-based formats in CBT trials were ones that we
considered sufficiently dissimilar to conceivably affect outcomes.
In these situations, we did not combine information across
therapy modalities, but we do present information about these
unique studies in results in the succeeding text.
We were not able to comment on trials comparing
pharmacological interventions with psychological interventions.
Our rigorous search did not reveal any trials that directly
compared a single pharmacological intervention with a single
behavioural intervention thereby preventing any qualitative
analysis. We were also unable to conduct network meta-analysis
given that the comparators in the available efficacy trials
differed. In the pharmacological efficacy trials, placebo was used
as the comparator against the active intervention, whereas in
psychological efficacy trials, the comparator used was waitlist
control. Conceptually, placebo and waitlist comparators are
identify studies (Berkman et al., 2006; Berkman, Lohr, & Bulik, 
2007; Brownley et al., 2007). We also hand searched reference lists 
and relevant systematic reviews and reviewed articles suggested by 
members of our technical expert panel.
Study selection
Trained pairs of research team members selected abstracts for 
full-text review if they met the predefined eligibility inclusion 
and exclusion criteria. We conducted a dual review of all trials 
selected for full-text review. We excluded studies at this stage if 
both reviewers agreed that it did not meet eligibility criteria. If 
reviewers did not agree on inclusion, they resolved the 
disagreement through discussion or with help of a third, senior 
reviewer.
Data abstraction
Based on the PICOTS framework for the full review (Berkman 
et al., 2015), we abstracted information on trial characteristics, 
study designs, methods, and results. One member of the research 
team abstracted relevant data from each included article. A senior 
member of the research team reviewed each abstraction for 
accuracy and completeness.
Risk of bias assessment and strength of evidence 
grading
We assessed the risk of bias for all included RCTs using the 
Cochrane risk-of-bias tool (Higgins et al., 2011). Two 
independent reviewers assessed the potential for selection bias, 
performance bias, attrition bias, detection bias, and outcome 
reporting bias and gave each study a grade of low, medium, or 
high risk of bias (Berkman et al., 2015). Disagreements on risk-
of-bias ratings were regularly resolved through discussion by the 
two reviewers or consultation with a third team member on an 
as-needed basis.
We graded the strength of evidence (SOE) for key outcomes of 
treatment comparisons as high, moderate, low, or insufficient, 
based on the Evidence-based Practice Center Methods Guide 
(Berkman et al., 2013; Berkman et al., 2014). The five domains, 
assessed independently by two reviewers, include study 
limitations, consistency, directness, precision, and reporting bias. 
The full report documents the risk-of-bias and SOE methods and 
grades (Berkman et al., 2015).
Data synthesis of pharmaceutical interventions
Only pharmacological interventions met the minimum threshold 
for pooled analysis (e.g., three or more studies with reasonably 
homogenous interventions, populations, and outcomes). Because 
these trials (of SGAs and lisdexamfetamine) were efficacy trials 
(i.e., placebo-controlled), we were interested in determining 
whether their effects differed. To explore this issue, comparative 
effectiveness analyses would ideally be drawn from head-to-head 
trials that directly compare two active interventions. Our search 
of the published literature revealed only a single head-to-head 
trial of pharmacological interventions (Leombruni et al., 2008). 
Therefore, as discussed in the succeeding text we used network 
meta-analysis to compare outcomes of lisdexamfetamine therapy 
with those of the SGAs (as a class) at the end of treatment. 
Network meta-analysis allows for the estimation of comparative
published efficacy results (Brownley et al., 2016) and in the full
report (Berkman et al., 2015).
Results
Description of studies
Our searches identified 4,794 potentially relevant citations
(Figure 1). The full systematic review included 87 of these
publications; this paper focuses on the 42 studies providing
evidence on the comparative effectiveness of treatment among
adults with BED. Consistent with our prespecified process, for
11 of the 30 included studies, the two independent risk-of-bias
assessors needed to reconcile their final rating. In all cases, the
initial risk-of-bias rating was either low or medium. Seven were
finalized asmedium risk-of-bias, whereas four were finalized as low.
A total of 12 trials provided evidence of comparative
effectiveness of pharmacological interventions. A single head-to-
head trial (Leombruni et al., 2008) compared two SGAs:
fluoxetine and sertraline. The remaining 11 pharmacological trials
(reported in 12 articles) contributed to the network meta-analysis
of major outcomes (trial characteristics reported in Appendix B).
Of these, eight involved SGAs (Arnold et al., 2002; Grilo, Masheb,
& Wilson, 2005; Guerdjikova et al., 2008; Guerdjikova et al., 2012;
Hudson et al., 1998; McElroy et al., 2000; McElroy et al., 2003;
Figure 1. Flow diagram of the literature search process for studies of binge-eating disorder. AHRQ Agency for Healthcare Research and Quality; KQ, key question
dissimilar as one involves active concurrent participation 
(receiving the placebo; Gupta & Verma, 2013); waitlist implies 
no concurrent participation. Participants randomized to a 
placebo condition are blinded to whether or not they are 
receiving the active intervention. Thus, expectations about 
treatment outcome are relevant in ways that are not as salient 
in waitlist control groups where participants are fully aware they 
are not actively receiving an intervention. Also, the waitlist 
control condition is designed such that participants do not have 
any contact with study personnel after the first (baseline) 
assessment, until the intervention period has ended. In contrast, 
participants in a placebo-controlled trial may have continued 
and consistent contact with study personnel by way of visits 
for treatment administration, phone contact to schedule visits, 
on-going measurement of interim outcomes and general 
attention by study personnel. These non-specific factors have 
been found to account for much of the outcome variance in 
clinical trials (Chatoor & Krupnick, 2001): thus, control 
conditions with varying levels of non-specific factors should be 
considered conceptually distinct.
Our search did not reveal comparative effectiveness trials that 
involved combination approaches (i.e., combining a 
pharmacological and psychological intervention) versus a 
different active treatment. All combination approaches were 
placebo-controlled trials and therefore covered in the previously
In short, both SGAs and lisdexamfetamine improved binge-
eating outcomes and eating-related psychopathology when
compared with placebo (Brownley et al., 2016). Network meta-
analysis revealed that lisdexamfetamine was superior to SGAs only
in achieving binge abstinence.
Comparative effectiveness of different levels of
therapist involvement in delivering cognitive
behavioural therapy
Two trials by the same group of researchers examined different
levels of therapist involvement in delivering group-based CBT
and reported up to 12-month follow-up data (Peterson et al.,
2009; Peterson et al., 2001; Peterson et al., 1998). One was a small
trial of 50 patients; the other was a larger trial of 190 patients.
Each trial compared (i) therapist-led CBT, (ii) partially
therapist-led CBT, and (iii) structured self-help CBT. Although
all forms of treatment involved manualized CBT delivered in a
Figure 2. Results of network meta-analyses comparing second generation anti-
depressants and lisdexamfetamine. CI, confidence interval; RR, Relative Risk;
SGA, second-generation antidepressants; YBOCS, Yale–Brown Obsessive
Compulsive Scale Modified for Binge Eating
White & Grilo, 2013) and three involved lisdexamfetamine 
(McElroy et al., 2015a; McElroy et al., 2015b; Shire Development 
LLC, 2014a, 2014b).
The evidence of comparative effectiveness of psychological 
treatments was reported in 18 trials (in 29 articles) (Carter & 
Fairburn, 1998; Castelnuovo, Manzoni, Villa, Cesa, & Molinari, 
2011; Cesa et al., 2013; De Zwaan et al., 2005; Grilo & Masheb, 
2005; Grilo, Masheb, Wilson, Gueorguieva, & White, 2011; Grilo, 
White, Wilson, Gueorguieva, & Masheb, 2012; Hilbert et al., 2012; 
Hilbert, Hildebrandt, Agras, Wilfley, & Wilson, 2015; Hilbert & 
Tuschen-Caffier, 2004; Le Grange, Gorin, Dymek, & Stone, 
2002; Masheb & Grilo, 2005; Masheb, Grilo, & Rolls, 2011; 
Munsch et al., 2007; Munsch, Meyer, & Biedert, 2012; Peterson, 
Mitchell, Crow, Crosby, & Wonderlich, 2009; Peterson et al., 
2001; Peterson et al., 1998; Pisetsky et al., 2015; Ricca et al., 
2010; Riva, Bacchetta, Baruffi, & Molinari, 2002; Robinson & 
Safer, 2012; Safer & Joyce, 2011; Safer, Robinson, & Jo, 2010; 
Sysko, Hildebrandt, Wilson, Wilfley, & Agras, 2010; Tasca, 
Balfour, Presniak, & Bissada, 2012; Tasca et al., 2006; Wilfley 
et al., 2002; Wilson, Wilfley, Agras, & Bryson, 2010). These 18 
trials examined various forms of CBT, IPT, BWL, dietary 
approaches, and inpatient interventions for managing BED (trial 
characteristics reported in Appendices C–F). The 18 trials 
presented 26 treatment comparisons. Of these, four were 
replicated in more than one trial and 22 were confined to a single 
trial each.
Comparative effectiveness of second-generation 
antidepressants versus Lisdexamfetamine
As described in Appendix B, 11 trials were available for network 
meta-analysis comparing SGAs (as a class) with lisdexamfetamine 
at the end of treatment (Arnold et al., 2002; Grilo et al., 2005; 
Guerdjikova et al., 2008; Guerdjikova et al., 2012; Hudson 
et al., 1998; McElroy et al., 2000; McElroy et al., 2015a; McElroy 
et al., 2003; McElroy et al., 2015b; Shire Development LLC, 
2014a, 2014b; White & Grilo, 2013). For these analyses, we 
included information from three trials comparing lisdexam-
fetamine with placebo and eight trials comparing SGAs with 
placebo; the SGAs included bupropion, citalopram, duloxetine, 
escitalopram, fluoxetine, fluvoxamine, and sertraline. A total of 
725 participants (517 lisdexamfetamine and 208 SGAs) 
constituted the treatment arms across these trials. All 11 trials 
provided data sufficient for the analysis of binge abstinence; 
six had data on binge-eating frequency (expressed in binge 
days), and six provided data on binge-eating related obsessions 
and compulsions [measured on the YBOCS-BE (Deal et al., 
2015) total score ranging from 0 to 40].
Figure 2 reports on the meta-analysis results comparing SGAs 
and lisdexamfetamine for abstinence, binge-eating frequency, 
and binge-eating obsessions and compulsions. Lisdexamfetamine 
was associated with statistically significant greater abstinence than 
SGA, relative risk 1.56 (95% CI, 1.06 to 2.29; moderate SOE for 
greater benefit). Differences between SGAs and lisdexamfetamine 
were not statistically significant for either binge frequency (mean 
difference in days per week 0.48; 95% CI, 1.17 to 0.20; low 
SOE for no difference) or obsessions and compulsions (mean 
difference 2.68; 95% CI, 5.41 to 0.06; low SOE for no 
difference).
Both trials reported improvements in other relevant outcomes
(e.g., eating-related psychopathology, BMI, and depressive
symptoms). These treatment comparisons, based on level of
therapist involvement, were not significantly different at either
end of treatment or 12-month followup; we graded SOE as low
for no treatment difference for all these other outcomes.
In short, each of the CBT treatment modalities (e.g., therapist-
led and structured self-help) produced some clinically meaningful
changes in abstinence and binge-eating frequency. However, the
range of benefits was wide at end of treatment: abstinence ranged
from 17.9% to 86.7% and binge-eating frequency from an average
of 6.3 episodes to 0.4 episodes in the past 28 days (Table 1). A
similarly wide range of benefits was also observed in both trials
at 12-month followup (Table 1). Thus, the available evidence
prevents us from reaching a definitive conclusion about their
comparative benefits for treating BED patients.
Comparative effectiveness of therapist-led
cognitive behavioural therapy versus therapist-led
behavioural weight loss
Two RCTs compared therapist-led CBT with therapist-led BWL,
both delivered in a group format (Grilo et al., 2011; Munsch
et al., 2007). Follow-up data were collected for up to 72 months,
but the majority of these data were not reported. Although the
two trials based CBT on the same manual (Fairburn, 1995;
Fairburn, Marcus, & Wilson, 1993), BWL was based on two
different manuals. The Munsch trial (Munsch et al., 2007) used
the manual ‘Weight Loss with Xenical’ (Margraf, 2000), whereas
Table 1 Outcomes of trials comparing variants of cognitive behavioural therapy for binge-eating disorder
Abstinence %
(Peterson et al., 2001; Peterson et al., 1998) (Peterson et al., 2009)
Baseline End of treatment 12 months Baseline End of treatment 12 months
CBT-TL (n = 16) 0 68.8 66.7 CBT-TL (n = 60) 0 51.7* 20.8
CBT-PTL (n = 19) 0 68.4 84.6 CBT-PTL (n = 63) 0 33.3 27.0
CBT-SSH (n = 15) 0 86.7 75.0 CBT-SSH (n = 67) 0 17.9 25.4
Binge frequency mean (SD)
Baseline End of treatment 12 months Baseline End of treatment 12 months
CBT-TL (n = 16) 3.4 (1.7) 0.7 (1.3) 0.5 (0.8) CBT-TL (n = 60) 24.6 (18.7) 6.3 (12.3)* 16.2 (19.4)
CBT-PTL (n = 19) 5.5 (6.5) 1.3 (3.4) 1.1 (2.7) CBT-PTL (n = 63) 21.9 (12.3) 9.7 (12.4) 12.3 (12.9)
CBT-SSH (n = 15) 3.1 (2.1) 0.4 (1.1) 1.0 (2.0) CBT-SSH (n = 67) 22.4 (13.7) 11.9 (13.2) 12.4 (13.7)
Body mass index mean (SD)
Baseline End of treatment 12 months Baseline End of treatment 12 months
CBT-TL (n = 16) 32.6 (8.2) 32.5 (8.9) 31.2 (7.9) CBT-TL (n = 60) 39.2 (8.3) 40.8 (11.7) 38.3 (8.5)
CBT-PTL (n = 19) 35.8 (6.0) 36.2 (5.5) 35.8 (7.0) CBT-PTL (n = 63) 40.7 (8.8) 40.8 (8.5) 40.4 (8.9)
CBT-SSH (n = 15) 33.6 (7.0) 32.4 (7.2) 32.8 (7.4) CBT-SSH (n = 67) 38.2 (7.2) 39.1 (10.6) 38.7 (10.6)
Depression symptoms mean (SD)
Baseline End of treatment 12 months Baseline End of treatment 12mo
CBT-TL (n = 16) 15.5 (9.9) 10.5 (9.9) 7.8 (8.1) CBT-TL (n = 60) 25.2 (10.9) 19.8 (11.3) 20.8 (12.0)
CBT-PTL (n = 19) 11.1 (9.1) 5.6 (3.6) 3.9 (3.7) CBT-PTL (n = 63) 20.4 (10.0) 17.7 (9.5) 17.8 (1.0)
CBT-SSH (n = 15) 13.5 (9.5) 9.0 (8.1) 6.6 (7.4) CBT-SSH (n = 67) 26.7 (11.2) 23.4 (13.4) 23.8 (12.4)
*p< .008 versus CBT-SSH; all other comparisons were non-significant.
BDI, Beck depression inventory; CBT-PTL, cognitive behavioural therapy, partially therapist-led; CBT-SSH, cognitive behavioural therapy, structured self-help; CBT-TL,
cognitive behavioural therapy, therapist-led; IDS-SR, inventory of depressive symptomatology, self-rated; n, number of participants.
group setting, the modalities differed in the amount of therapist 
contact that participants received. In the therapist-led arm, a 
clinician led the group for the entirety of each session. In the 
partially therapist-led group, participants watched a pre-recorded 
psychoeducational video (of the same therapist) during the first 
half of the session, and the therapist led the group discussion 
during the second half. In the structured self-help group, 
participants watched the same pre-recorded psychoeducational 
video as in the partially therapist-led condition, but a group 
member facilitated the second half of the session (so the only 
‘therapist contact’ that participants had was through the video). 
The randomized sample comprised a total of 240 participants 
(76 therapist-led CBT, 82 partially-therapist led CBT, and 82 
structured self-help CBT). Both trials reported on binge 
abstinence, binge-eating frequency, BMI, and depressive 
symptoms.
As documented in Table 1, across all comparisons, only two 
statistically significant differences emerged. Both were from the 
larger trial (N = 190) (Peterson et al., 2009). Specifically, 
therapist-led CBT was associated with significantly greater 
binge abstinence and greater reductions in binge-eating 
frequency than structured self-help CBT at end of treatment; 
however, differences were not significant at 12-month followup 
(Peterson et al., 2009). In contrast, the smaller trial did not 
find significant differences between treatment arms. Because 
of the inconsistency in the results across studies, SOE for 
therapist-led CBT versus structured self-help CBT for binge-
eating outcomes was insufficient.
in BMI was substantial: at end of treatment, those receiving
CBT decreased BMI by only an average of 0.41 points whereas
those receiving BWL decreased BMI by an average of 2.2 points.
However, by 12-month followup, this difference was no longer
statistically significant, as those receiving BWL tended to gain
weight. Finally, depression symptoms at end-of-treatment and
followup improved for patients in both CBT and BWL groups,
but the changes did not differ significantly between the two
interventions (low SOE for no difference). As with the trials
comparing different CBT variations, despite the fact that
comparisons between BWL and CBT were mixed for abstinence
and not significantly different for depressive symptoms, both
treatments consistently produced better outcomes between
baseline to the end of treatment across trials and these findings
tended to persist at 12-month followup (Table 2).
Summary of the strength of evidence for
comparative effectiveness
Table 3 presents the SOE grades for the comparative analyses
presented previously. The majority of grades for comparisons of
psychological interventions were low for no difference; those for
Table 2 Outcomes of trials comparing cognitive behavioural therapy with behavioural weight loss for binge-eating disorder
Abstinence %










CBT-TL (n = 44) 0 41 52 NR CBT-TL
(n = 45)
0 44.40 51.1 51.10
BWL-TL (n = 36) 0 58 50 NR BWL-TL
(n = 45)
0 37.80 33.3 35.60
Binge frequency mean (SD)
Baseline End of
treatment
12 months 72 months Baseline End of
treatment
6 months 12 months
CBT-TL (n = 44) 3.81 (3.47) 0.14 (0.45)** 0.52 (1.59)* NR* CBT-TL
(n = 45)
15.6 (8.0) 2.2 (3.8) 2.7 (8.5)** 2.4 (8.1)****
BWL-TL (n = 36) 4.10 (3.71) 1.15 (1.89) 1.50 (2.14) NR BWL-TL
(n = 45)
14.9 (8.5) 4.6 (11.0) 5.5 (7.6) 4.6 (6.0)
Body mass index mean (SD)
Baseline End of
treatment
12 months 72 months Baseline End of
treatment
6 months 12 months
CBT-TL (n = 44) 33.6 (4.31) 33.58 (4.53) 33.10 (5.04) 33.5 (3.8) CBT-TL
(n = 45)
39.3 (6.1) 38.5 (5.7) 38.7 (5.7) 38.3 (6.0)
BWL-TL (n = 36) 34.36 (3.74) 32.29 (4.00)* 33.18 (4.17) 31.5 (5.2) BWL-TL
(n = 45)





12 months 72 months Baseline End of treatment 6 months 12 months
CBT-TL (n = 44) 15.14 (9.16) 9.16 (7.80) 8.23 (11.31) NR CBT-TL
(n = 45)
15.2 (6.9) 10.1 (8.8) 8.1 (7.3) 9.1 (7.9)
BWL-TL (n = 36) 11.82 (6.72) 9.19 (6.54) 7.76 (6.48) NR BWL-TL
(n = 45)
15.9 (8.4) 11.1 (8.3) 11.1 (8.7) 9.6 (7.7)
the Grilo trial (Grilo et al., 2011) used the ‘Lifestyles, Exercises, 
Attitudes, Relationships, and Nutrition (LEARN)’ manual 
(Brownell, 2000). The randomized sample comprised 170 
participants (89 CBT and 81 BWL).
As shown in Table 2, both trials reported significantly greater 
reductions in binge-eating frequency for participants receiving 
CBT than for those receiving BWL at end of treatment and up 
to 72 months followup. We graded the SOE as low for CBT being 
more beneficial for reducing binge eating. However, neither trial 
reported a significantly greater benefit of CBT on binge 
abstinence. In fact, in the Munsch trial (Munsch et al., 2007), 
the percentage of patients abstinent at the end of treatment was 
significantly lower in the CBT group (41%) than the BWL group 
(58%); however, by 12-month followup, this differential 
essentially disappeared. Because of these mixed abstinence results 
from these two trials, we graded SOE for abstinence as 
insufficient.
Both trials reported statistically significant greater reductions in 
BMI for participants receiving BWL than for those receiving CBT 
at end of treatment (but not followup); we graded SOE as 
moderate for BMI benefit from BWL. The magnitude of change
*p < .001.
**p < 0.05; all other comparisons were non-significant.
BWL-TL, behavioural weight loss, therapist-led; CBT-TL, cognitive behavioural therapy, therapist-led; n, number of participants; NR, not reported.
The treatments compared in these single trials focused on CBT
in four trials (Carter & Fairburn, 1998; Hilbert & Tuschen-
Caffier, 2004; Le Grange et al., 2002; Ricca et al., 2010); BWL or
dietary interventions in four trials (De Zwaan et al., 2005; Grilo
& Masheb, 2005; Grilo et al., 2005; Masheb et al., 2011);
dialectical behavioural therapy (DBT) in one trial (Safer et al.,
2010); IPT in three trials (Tasca et al., 2006; Wilfley et al., 2002;
Wilson et al., 2010); and inpatient treatment programs in three
trials (Castelnuovo et al., 2011; Cesa et al., 2013; Riva et al., 2002).
Discussion
Clinical implications of findings
Results from the current comparative effectiveness review on
interventions for BED are based on 12 relevant trials of
pharmaceutical interventions and 18 of various psychological
interventions. Network meta-analysis and qualitative results
revealed important information on which interventions might
be more effective in improving at least one type of outcome for
patients with BED; these treatments include lisdexamfetamine,
therapist-led CBT, and BWL. These interventions produced
reductions in key BED outcomes including binge-eating
abstinence and binge-eating frequency, but they did not
demonstrate superiority on all relevant outcomes (e.g., BMI,
depressive symptoms). Such information is crucial for health care
decisionmaking as patients and clinicians face many options from
which to choose; thus, our results help key stakeholders make
informed decisions on which treatments might provide important
benefits.
Table 3 Strength of evidence for comparative effectiveness of interventions for binge-eating disorder
Outcome Treatment group 1 Treatment group 2 N (Trials) Summary Strength of evidence
Abstinence from binge eating Second-generation antidepressants Lisdexamphetamine 791 (11) No difference* Moderate for no difference
CBT Therapist-led CBT Partially Therapist-led 158 (2) No difference** Low for no difference
CBT Therapist-led CBT Structured Self-help 158 (2) Mixed results- Insufficient
CBT Partially Therapist-led CBT Structured Self-help 164 (2) No difference** Low for no difference
CBT Therapist-led BWL Therapist-led 170 (2) Mixed results Insufficient
Binge-eating frequency Second-generation antidepressants Lisdexamphetamine 649 (6) No difference* Moderate for no difference
CBT Therapist-led CBT Partially Therapist-led 158 (2) No difference** Low for no difference
CBT Therapist-led CBT Structured Self-help 158 (2) Mixed results Insufficient
CBT Partially Therapist-led CBT Structured Self-help 164 (2) No difference** Low for no difference
CBT Therapist-led BWL Therapist-led 170 (2) CBT better** Low for CBT benefit
Body mass index CBT Therapist-led CBT Partially Therapist-led 158 (2) No difference** Low for no difference
CBT Therapist-led CBT Structured Self-help 158 (2) No difference** Low for no difference
CBT Partially Therapist-led CBT Structured Self-help 164 (2) No difference** Low for no difference
CBT Therapist-led BWL Therapist-led 170 (2) BWL better* Moderate for BWL benefit
Symptoms of depression CBT Therapist-led CBT Partially Therapist-led 158 (2) No difference** Low for no difference
CBT Therapist-led CBT Structured Self-help 158 (2) No difference** Low for no difference
CBT Partially Therapist-led CBT Structured Self-help 164 (2) No difference** Low for no difference
CBT Therapist-led BWL Therapist-led 170 (2) No difference** Low for no difference
Eating-related psychopathology Second-generation antidepressants Lisdexamphetamine 643 (6) No difference* Moderate for no difference
BWL, behavioural weight loss; CBT, cognitive behavioural therapy.
*End of treatment.
**End of followup.
the pharmaceutical findings were moderate for no difference. 
Three CBT or CBT-BWL comparisons were from trials with 
mixed or conflicting results and were graded insufficient evidence. 
Finally, one CBT-BWL comparison was low for CBT benefit; 
another was moderate for BWL benefit.
Treatment comparisons presented in single 
randomized controlled trials
The trials detailed previously were the only ones identified in the 
search that allowed for combined analysis. However, the search 
did reveal an additional 23 treatment comparisons, including 
one pharmacological comparison and 22 psychological 
comparisons (Appendices C–G). With regard to the former, a 
single head-to-head trial compared the SGAs fluoxetine and 
sertraline (Leombruni et al., 2008); although both interventions 
produced reductions in binge-eating frequency, body weight, 
eating-related psychopathology, and symptoms of depression, 
differences between the two treatments were not significant. 
Given that the results were confined to a single trial in a small 
sample (N = 44), the SOE was insufficient to determine their 
comparative effectiveness. With regard to the psychological 
interventions, although the remaining 22 treatment comparisons 
involved somewhat similar modalities, we judged, based on our 
protocol and during data synthesis, that the comparators or 
formats of the interventions (or both) were too dissimilar to allow 
for any combined analysis (even qualitatively). Because of this 
decision and because the comparisons were restricted to relatively 
small trials, we graded the SOE for all outcomes for these 
comparisons as insufficient.
effective pharmaceutical options from which clinicians and BED
patients can choose if they prefer a medication regimen.
Similarly, in relation to psychological interventions, the
collective results from this paper and the larger report suggest that
patients and clinicians have a variety of effective choices. Not
surprisingly, therapist-led CBT appears to be more effective at
reducing binge-eating frequency, whereas therapist-led BWL was
better at reducing weight. These results might be expected given
that CBT for BED was designed to help patients either abstain
from or reduce overall binge eating, whereas BWL was designed
primarily to aid with weight loss. This pattern of results suggests
that it is imperative for patients and clinicians to identify mutual
goals for treatment in an effort to select interventions that have
the best fit. Additionally, despite the strength of the evidence for
therapist-led CBT, we note that many individuals with BED do
not have access to therapists who are knowledgeable about
BED-specific treatments. Therefore, the generalizability and
implementation of the findings from the current review may be
limited insofar as eating disorder specialists are not widely
available. Our review does highlight favourable outcomes from a
self-help approach to CBT (Carter & Fairburn, 1998; Grilo &
Masheb, 2005; Peterson et al., 2009; Peterson et al., 1998; Wilson
et al., 2010). Such a program might help overcome the above
barrier to treatment. Moreover, it is consistent with practice
guidelines from the National Institute of Health and Care
Excellence (NICE) in the United Kingdom, which recommend
self-help formats of CBT.
Limitations in the evidence base
Despite the review revealing 27 treatment comparisons relevant
for comparative effectiveness analyses, our ability to draw more
definitive conclusions was considerably influenced by the fact that
23 of the 27 relevant treatment comparisons were limited to a
single trial (SOE insufficient in all cases). Although results of these
individual trials typically reflected improvements in BED
outcomes in one or both patient groups, a lack of replication
prevented us from synthesizing evidence across studies. For that
reason, we could not reach conclusions about the comparative
effectiveness of these approaches. Interventions such as IPT and
DBT, albeit in single studies, demonstrated promising results at
both end of treatment and long-term followup. Hence, these
approaches may well merit additional trials to determine their
comparative effectiveness.
Furthermore, the applicability of many of our results is
constrained as well. For instance, the majority of the trials in this
review involved primarily middle-aged white women, many of
whom were overweight or obese. Therefore, the extent to which
these findings can be extended to other age groups, to men, to
more ethnically and racially diverse populations, or to those
BED patients who may be closer to normal weight or BMI is
unclear.
Finally, although some of the comparative effectiveness trials of
psychological therapies reported data past the end of treatment
measurements, none of the pharmacological trials reported data
beyond that point. This scarcity of high-quality, longer-term
evidence affects our ability to understand how long the shorter-
term benefits persist and, subsequently, how long an individual
might need to be prescribed a particular medication.
For example, comparisons of pharmacological interventions 
found lisdexamfetamine to be superior to SGAs (as a class) in 
increasing binge abstinence (moderate SOE for lisdexamfetamine 
benefit); however, neither treatment was better than the other 
for decreasing binge-eating frequency and obsessions and 
compulsions (moderate SOE for no difference). Similarly, 
therapist-led CBT was superior to therapist-led BWL in decreasing 
binge frequency at both end of treatment and up to 12-month 
followup (low SOE). By contrast, therapist-led BWL was better 
than CBT in reducing BMI, but only at end of treatment 
(moderate SOE); patients receiving BWL tended to regain the 
weight they had lost during treatment, so the benefits from BWL 
did not persist over time. Comparisons of CBT and BWL on other 
relevant outcomes (e.g., BMI or depressive symptoms) revealed 
nonsignificant differences (low SOE for no difference). 
Additionally, data regarding several levels of therapist involvement 
in CBT were mixed; the superiority of therapist-led CBT over 
structured self-help CBT on binge-eating frequency and binge-
eating abstinence was found only in the larger of two trials.
The larger pattern of nonsignificant differences between 
treatments does not imply a lack of significant positive effects 
on important patient outcomes. Various psychological 
interventions (e.g., CBT, IPT, and DBT) all improved relevant 
BED outcomes. However, because both treatment arms produced 
significant effects over baseline levels, these trials did not reflect 
superiority for major outcomes of interest in comparisons across 
the various treatments. Thus, despite substantial evidence 
supporting the efficacy of many of these interventions (Brownley 
et al., 2016), the extent to which one treatment is more effective 
than another has been demonstrated only for lisdexamfetamine 
(versus SGAs) and therapist-led CBT and BWL (compared with 
each other) and, then, only for certain outcomes.
That lisdexamfetamine demonstrated superiority to SGAs only 
on the outcome of binge-eating abstinence merits particular 
consideration given lisdexamfetamine’s recent FDA approval for 
treating BED patients. Data from the early clinical trials suggested 
that this medication is a safe and efficacious intervention that helps 
improve relevant binge-eating outcomes and reduce weight 
(Brownley et al., 2016). However, not all individuals with BED 
may be candidates for this intervention, even with its FDA labelling, 
given that the US Drug Enforcement Administration classifies 
lisdexamfetamine as a Schedule II drug. This means that clinicians 
should not generalize current findings to patients with a history of 
stimulant or other substance use disorder, suicide attempt, mania, 
or cardiac disease, as such patients might be more susceptible to 
abuse or side effects than patients without such a history.
Our network meta-analysis suggests, therefore, that SGAs 
represent a reasonable pharmacological alternative option for 
reducing binge eating and improving eating-related 
psychopathology for patients who are not candidates for 
lisdexamfetamine. Our meta-analyses used eight different SGAs; 
each had demonstrated significant reductions in binge eating 
and improvements in eating-related psychopathology (Berkman 
et al., 2015). Having alternative pharmacological options increases 
the ability of clinicians to manage BED effectively across their 
patient populations. Although a lack of replication for specific 
SGAs required us to analyse them as a class, the collective 
evidence is encouraging because this synthesis documents several
interventions into clinical practice. For instance, many of the
psychological treatment trials involve doctoral-level therapists,
and trials take place outside traditional health care settings or
systems that might be able to implement such programs. Thus,
the need is critical for researchers to develop innovative ways
to translate the findings from such trials into clinical practice
such that all individuals with BED, not just those who are able
to access clinical trials, might benefit from evidence-based
treatment.
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